3,327 reports of this reaction
2.4% of all DROSPIRENONE AND ETHINYL ESTRADIOL reports
#10 most reported adverse reaction
GENERAL PHYSICAL HEALTH DETERIORATION is the #10 most commonly reported adverse reaction for DROSPIRENONE AND ETHINYL ESTRADIOL, manufactured by Bayer HealthCare Pharmaceuticals Inc.. There are 3,327 FDA adverse event reports linking DROSPIRENONE AND ETHINYL ESTRADIOL to GENERAL PHYSICAL HEALTH DETERIORATION. This represents approximately 2.4% of all 140,358 adverse event reports for this drug.
Patients taking DROSPIRENONE AND ETHINYL ESTRADIOL who experience general physical health deterioration should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
GENERAL PHYSICAL HEALTH DETERIORATION is a less commonly reported adverse event for DROSPIRENONE AND ETHINYL ESTRADIOL, but still significant enough to appear in the safety profile.
In addition to general physical health deterioration, the following adverse reactions have been reported for DROSPIRENONE AND ETHINYL ESTRADIOL:
The following drugs have also been linked to general physical health deterioration in FDA adverse event reports:
GENERAL PHYSICAL HEALTH DETERIORATION has been reported as an adverse event in 3,327 FDA reports for DROSPIRENONE AND ETHINYL ESTRADIOL. This does not prove causation, but indicates an association observed in post-market surveillance data.
GENERAL PHYSICAL HEALTH DETERIORATION accounts for approximately 2.4% of all adverse event reports for DROSPIRENONE AND ETHINYL ESTRADIOL, making it a notable side effect.
If you experience general physical health deterioration while taking DROSPIRENONE AND ETHINYL ESTRADIOL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.